A new treatment has been associated with rapid and large reductions in vertebral fracture, according to a large study presented at the Annual European Congress of Rheumatology. Continue reading
Chronic pain in one body part may distort the intensity with which a key brain region perceives pain everywhere else, says a new study in eLife. Continue reading
Experts are developing compounds that could allow the pain-relieving effects of ibuprofen to last longer, they report in Molecular Pharmaceutics. And the approach could also be used to deliver other drugs orally that currently can only be taken intravenously.
Metal-organic frameworks are compounds made of metal ions linked to organic ligands, for drug delivery. Active ingredients can be packed inside the metal organic frameworks. They are porous, and some dissolve in water so are good candidates for drug couriers.
The researchers loaded ibuprofen into metal organic frameworks. The compounds were found to reach the bloodstream (of mice) quickly and lasted for twice as long as ibuprofen salts, which are the active ingredient in liquid gel formulations.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.
People with acute low back pain may experience modest improvements in pain and function after spinal manipulation therapy, says research in the Journal of the American Medical Association.
Experts reviewed 26 studies about spinal manipulation (how well it works and whether it can be harmful) and compared it to other therapies for adults with acute low back pain. Continue reading
Commonly used non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen may have little benefit in terms of reducing back pain, and potentially put people at risk of side effects, says research in the Annals of the Rheumatic Diseases.